Abstract
Both caffeine and theophylline have a variety of roles in regulating inflammatory responses. At pharmacologically relevant concentrations most of the effects of these commonly used methylxanthines are attributable to adenosine receptor blockade and histone deacetylase activation. In addition, at higher concentrations methylxanthines can suppress inflammation by inhibiting phosphodiesterases, thereby elevating intracellular cyclic adenosine monophosphate levels. In summary, methylxanthines regulate inflammation by multiple mechanisms.
Access provided by Autonomous University of Puebla. Download chapter PDF
Similar content being viewed by others
Keywords
- Asthma
- Arthritis
- Chronic obstructive pulmonary disease
- Cytokine
- Macrophage
- Methothrexate
- Monocyte
- Neutrophil
- Tumor necrosis factor
- Protein kinase A
1 Introduction
Caffeine is a nonselective adenosine receptor antagonist, and it is believed that at concentrations achieved during normal human consumption, caffeine exerts its biological effects through antagonism of adenosine receptors (Fredholm et al. 1999). Similar to caffeine, theophylline is a nonselective albeit more potent antagonist of adenosine receptors (Fredholm et al. 2001). Adenosine is an extracellular purine nucleoside signaling molecule, which regulates cell and tissue function both in health and in disease (Hasko et al. 2008). Adenosine is generated following the degradation of its precursor, ATP, a process which can occur both extra- and intracellularly. ATP, a mostly intracellular molecule, is liberated from the cell following stressful and injurious events, and is metabolized to adenosine via a cascade of ectonucleotidases, including CD39 (nucleoside triphosphate diphosphorylase) and CD73 (5′-ectonucleotidase) (Yegutkin 2008). Adenosine that accumulates intracellularly following ATP metabolism is extruded from the cell via nucleoside transporters (Volonte and D’Ambrosi 2009). Cells of the immune/inflammatory system, including neutrophils, mast cells, endothelial cells, lymphocytes, and platelets, have been appreciated as the most prodigious sources of extracellular adenosine (Eltzschig et al. 2008; Hasko et al. 2008). In addition to serving as a source for adenosine release, immune cells are also among the most widely studied cell types targeted by the regulatory influences of adenosine (Deaglio et al. 2007; Erdmann et al. 2005; Feoktistov and Biaggioni 1995; Fozard et al. 1996; Hasko et al. 2007, 2008; Holgate 2005; Sitkovsky 2009).
2 Adenosine Receptor Expression in the Immune System
Adenosine produces its biological effects by binding to and activating one or more of four membrane-spanning adenosine receptors, designated A1, A2A, A2B, and A3. All four adenosine receptors contain seven transmembrane domains and couple to intracellular GTP binding proteins (G proteins). Adenosine elicits activation of A1, A2A, and A3 receptors with EC50 values that range from 0.01 to 1 μM, and A2B receptor activation occurs at adenosine levels that exceed 10 μM (EC50 24 μM) (Fredholm et al. 2001). Because physiological adenosine concentrations are less than 1 μM, physiological levels of adenosine can activate only A1, A2A, and A3 receptors, and A2B receptor activation requires pathophysiological conditions (Fredholm 2007). In addition to adenosine concentrations at the cell surface, receptor density and the functionality of the intracellular signaling pathways coupled to adenosine receptors are also key factors in dictating the nature and magnitude of the effect of adenosine on the cell. For example, A2A receptor activation inhibits production of the T helper (Th)-1-inducing cytokine interleukin (IL)-12 more potently by human monocytes that are pretreated with the proinflammatory cytokine IL-1 or tumor necrosis factor (TNF)-α, mediators that also increase A2A receptor expression in these cells (Khoa et al. 2001). In addition, the effect of adenosine can also be affected by the polarized localization of adenosine receptors: A3 adenosine receptors accrue at the leading edge of migrating neutrophils and are instrumental in directing the movement of cells in response to chemotactic mediators (Chen et al. 2006). Finally, it is important to keep in mind that results regarding adenosine receptor function in one species cannot be readily extrapolated to another one, because sequence differences in cloned adenosine receptors have been shown to be associated with differential pharmacological responses to selective agonists and antagonists. In this regard, A3 receptors were not even discovered until they were cloned (Zhou et al. 1992), because the A3 receptor, especially in rodents, is insensitive to caffeine and theophylline, antagonists which had been pivotal in identifying adenosine-receptor-mediated effects.
3 Adenosine Receptor Signaling in the Immune System
Adenosine receptors in general dictate cell function through coupling to G proteins, but some G-protein-independent actions have also been reported (Fredholm et al. 2007). Adenosine receptors were initially classified as A1 [cyclic AMP (cAMP)-decreasing] or A2 (cAMP-increasing) receptors (van Calker et al. 1979). Subsequently the cAMP-increasing A2 receptors were divided into two groups: high-affinity A2A receptors and low-affinity A2B receptors (Bruns et al. 1986). More recent studies have revealed that in addition to A1 receptors, A3 receptors also decrease intracellular cAMP concentrations (Jin et al. 1997). In addition to signaling via the adenylyl cyclase–cAMP system, adenosine receptors can signal through a variety of other pathways. A2A receptors, as other Gs-protein-coupled receptors, signal chiefly via the adenylate cyclase–cAMP–protein kinase A (PKA) canonical pathway, but they can also activate exchange factor directly activated by cAMP (Epac) (Fredholm et al. 2007). Signaling downstream from PKA occurs through phosphorylation of the transcription factor CREB on serine residue 133, leading to direct CREB-mediated transcriptional activation (Nemeth et al. 2003). Activated CREB can also modulate gene expression indirectly by competing with nuclear factor (NF)-κB or other transcription factors for an important cofactor, CBP (Fredholm et al. 2007). In other cell types, adenosine A2A receptors stimulate collagen production via mitogen-activated protein (MAP) kinases (Che et al. 2007) and inhibit neutrophil superoxide production through activation of protein phosphatases (Revan et al. 1996). Furthermore, recent results implicated CEBPβ in the stimulatory effect of A2A receptor agonists on IL-10 production by Escherichia coli-challenged macrophages (Csoka et al. 2007). A2B receptor stimulation can induce both adenylyl cyclase activation via Gs and phospholipase C activation via Gq (Feoktistov and Biaggioni 1997). Interaction between these two pathways is important for upregulation of IL-4 production by mast cells upon A2B receptor activation (Ryzhov et al. 2006). Specifically, Gq-mediated activation of phospholipase Cβ causes calcium mobilization and an increase in NFATc1-dependent IL-4 transcription, whose response is further facilitated by Gs-mediated NFATc1 protein accumulation. Traditionally, A3 receptor activation is linked to Gi-mediated inhibition of adenylyl cyclase and Gq-mediated stimulation of phospholipase C (Gessi et al. 2008) and A3 receptors can activate phospholipase D, RhoA, WNT, MAP kinase and phosphatidylinositol 3-kinase pathways in governing cell function. For example, A3-receptor-mediated augmentation of histamine released in sensitized murine mast cells was blocked by inactivating Gi proteins with pertussis toxin and by using pharmacological phosphatidylinositol 3-kinase inhibitors(Zhong et al. 2003). Caffeine and theophylline block A1, A2A, and A2B receptors at pharmacologically relevant concentrations but it appears that these methylxanthines are not potent A3 receptor antagonists (Fredholm et al. 1999). Although there is controversy regarding what constitutes relevant caffeine concentrations in the immune system (Horrigan et al. 2006), the inhibitory effect of adenosine on formyl-Met-Leu-Phe (fMLP)-stimulated respiratory burst in neutrophil leukocytes was reversed by 30 μM caffeine (Fredholm et al. 1996), a concentration that occurs in plasma following consumption of caffeine-containing beverages (Fredholm et al. 1999). In the same study, theophylline proved to be an antagonist of adenosine receptors and it was more potent than caffeine. In addition to its effect on neutrophil respiratory burst, caffeine inhibited the adenosine-receptor mediated accumulation of cAMP in rat thymocytes with a K i value of approximately 20 μM (Fredholm and Sandberg 1983). Theophylline was slightly more potent and its K i value was approximately 10 μM.
4 Caffeine and Theophylline Are Phosphodiesterase Inhibitors at High Concentrations
Higher concentrations of both caffeine and theophylline inhibit cAMP phosphodiesterase (PDE) (Beavo et al. 1971). Inhibition of PDEs by caffeine or theophylline generally requires concentrations of 100–1,000 μM, which typically exceeds the concentrations observed in blood following normal oral dosing and can be associated with toxicity (Sawynok and Yaksh 1993). Nevertheless, it is plausible that some of the biological effects of these methylxanthines are due to PDE inhibition.
5 Theophylline as a Histone Deacetylase Activator
Expression of inflammatory gene expression is governed by a balance between histone acetylation and deacetylation (Barnes 2006). Inflammatory stimuli activate transcription factors such as NF-κB, which leads to histone acetylation and increased inflammatory gene expression. This process is reversed by recruitment of histone deacetylases to the promoter of inflammatory genes. Recent studies have shown that theophylline at clinically relevant concentrations is an activator of histone deacetylases, which explains its anti-inflammatory effects especially in combination with glucocorticoids (Cosio et al. 2004).
6 Effect of Methylxanthines on Inflammatory Cells
6.1 Caffeine
On the basis of the fact that caffeine plasma concentrations rarely exceed 50–60 μM during normal human consumption (Fredholm et al. 1999), we will first consider studies that showed caffeine being efficacious at altering inflammatory cell function at these low concentrations. Sullivan et al. (1995) demonstrated that caffeine increased chemiluminescence and myeloperoxidase release by lipopolysaccharide (LPS)-primed, fMLP-stimulated mixed leukocyte cultures, and increases were already evident at 10 μM caffeine. Consistent with the fact that caffeine antagonizes adenosine receptors at this concentration, addition of the adenosine-degrading enzyme adenosine deaminase abolished the effect of caffeine, indicating that caffeine acted by altering an endogenous adenosine response. In addition, the possibility of PDE inhibition as a mechanism for the enhancing effect of caffeine on leukocyte activation was excluded by a lack of effect of caffeine on leukocyte cAMP levels. In a more recent study, 50 μM caffeine decreased TNF-α production by LPS-activated cord blood (neonatal) monocytes by 20% (Chavez-Valdez et al. 2009). In the same study, however, caffeine failed to affect TNF-α production by adult monocytes.
Caffeine at concentrations of 100 μM or higher appears to downregulate inflammatory cell function. Horrigan et al. (2004) found that caffeine suppressed TNF-α release by LPS-stimulated human whole blood at 100 μM by approximately 40% in a cAMP-PKA dependent fashion. In addition, the production of IL-1β, IL-12, and IL-10 was not affected by 100 μM caffeine (Horrigan et al. 2004). In another study, caffeine was shown to decrease colony formation in cultures of murine bone-marrow-derived macrophages, and again, 100 μM was the lowest effective concentration (Inouye and Wharton 1986).
6.2 Theophylline
Theophylline has been used as a bronchodilator in the therapy of asthma and chronic obstructive pulmonary disease (COPD) for several decades. Its therapeutic concentration is between 55 and 110 μM and it causes unacceptable side effects above 110 μM (Ito et al. 2002). It has long been suggested that theophylline may exert some of its beneficial effects in asthma and COPD by downregulating inflammation. One widely held view is that the beneficial effect of theophylline is secondary to its ability to block A2B receptors (Hasko et al. 2009). This is based, in part, on recent in vivo evidence (Mustafa et al. 2007) documenting that selective antagonists of adenosine A2B receptors inhibit airway inflammation and airway reactivity induced by allergen or AMP in a murine asthma model. The contribution of A2B receptor blockade to the anti-inflammatory effects of theophylline is also underlined by the observation that at therapeutic concentrations, theophylline is a relatively potent A2B receptor antagonist. Although A2B receptors on mast cells seem to be major players in triggering the lung inflammatory response in asthma and COPD (Polosa and Holgate 2006), proinflammatory effects of A2B receptor stimulation have also been observed with human bronchial smooth-muscle cells (Zhong et al. 2004), human bronchial epithelial cells (Zhong et al. 2006), and human lung fibroblasts (Zhong et al. 2005), which produce increased levels of IL-6 (Zhong et al. 2004, 2005) and IL-19 (Zhong et al. 2006) following A2B receptor activation.
In addition to A2B receptors, theophylline blocks A1 and A2A receptors at therapeutically relevant concentrations and thus it can reverse the effects of endogenously released adenosine, resulting in both pro- and anti-inflammatory effects depending on which adenosine receptors are expressed. For example, 10 μM theophylline enhanced TNF-α production by human monocytes stimulated with advanced glycation end products, an effect that was postulated to be secondary to blockade of anti-inflammatory adenosine (A2A or A3) receptors on monocytes (Meiners et al. 2004). Similar to TNF-α production by monocytes, theophylline at therapeutically relevant concentrations (maximal efficacy at 50 μM) augmented superoxide production by fMLP-activated neutrophils (Yasui et al. 2000b). Because 8-sulfophenyltheophylline, a nonselective adenosine receptor antagonist, reproduced the stimulatory effect of theophylline on superoxide production, it was concluded that theophylline acts by antagonizing adenosine receptors. Finally, 50 μM theophylline was shown to accelerate human granulocyte apoptosis (Yasui et al. 1997, 2000a), an observation consistent with an adenosine-receptor-mediated effect, because adenosine can delay the apoptosis of granulocytes (Walker et al. 1997) and other adenosine receptor antagonists can mimic the effect of theophylline (Yasui et al. 2000a).
In addition to blockade of adenosine receptors, recent studies have revealed a further mechanism that can explain the anti-inflammatory effects of theophylline in asthma. This new evidence is based on the idea that inflammatory gene expression is regulated by a balance between histone acetylation and deacetylation (Barnes 2006). It appears that theophylline is able to tip this balance in favor of histone deacetylation, resulting in decreased inflammatory gene expression (Ito et al. 2002).
Lastly, theophylline has anti-inflammatory effects in various in vitro cellular systems when used at therapeutically irrelevant, high concentrations. Theophylline inhibited TNF-α production by LPS-stimulated human mononuclear cells at 200–1,000 μM (Endres et al. 1991); this effect was mediated by inhibition of PDE. In addition, theophylline decreased arachidonate (Hichami et al. 1995), thromboxane B2, (Baker and Fuller 1992), and lysosomal enzyme (Hichami et al. 1995) release by stimulated mononuclear cells at supratherapeutic concentrations.
7 Enprofylline is Anti-inflammatory by Blocking A2B Receptors
On the basis of the efficacy of theophylline as an antiasthma drug (Holgate 2005), efforts to develop a similar xanthine-based compound with a better safety profile led to the development of enprofylline (3-propyl xanthine). It was subsequently demonstrated that similar to theophylline, enprofylline can weakly block A2B receptors on mast cells, which might explain its efficacy as an antiasthma agent. The advantage of enprofylline over theophylline is that enprofylline is a selective A2B antagonist, whereas theophylline blocks other adenosine receptors as well (Fozard and Hannon 1999).
8 Effects of Methylxanthines in Inflammatory States
8.1 Caffeine Exacerbates Acute Inflammatory Liver Injury by Blocking the Physiological Anti-inflammatory Effect of Endogenous Adenosine
Ohta and Sitkovsky (2001) demonstrated that endogenous adenosine by engaging A2A receptors has a nonredundant role in the prevention of inflammatory liver damage induced by concanavalin A. They showed that mice deficient in A2A receptors exhibited increased and protracted production of proinflammatory cytokines, including TNF-α and interferon-γ, which was paralleled by augmented biochemical and histological signs of liver injury. These results raised the possibility that caffeine acting as an A2A receptor antagonist might interfere with the endogenous protective mechanism rendered by adenosine–A2A receptor interaction. To address this possibility, Ohta et al. (2007) injected mice with 20 mg/kg caffeine, which corresponds with caffeine amounts ingested during normal human consumption (Fredholm et al. 1999), before inducing liver injury using concanavalin A. The results showed that caffeine exacerbated liver injury as determined by biochemical and histological analysis, and the increased liver injury coincided with increased production of harmful proinflammatory cytokines.
To investigate the role of A2A-receptor-mediated signaling in the exacerbation of liver injury following caffeine administration, caffeine (10 and 20 mg/kg) was injected into A2A receptor knockout and wild-type mice and liver injury was induced using concanavalin A (Ohta et al. 2007). While caffeine produced an exacerbated liver injury in wild-type mice, knockout mice failed to respond to caffeine with increased acute liver injury, confirming that caffeine enhances liver injury through blocking the action of endogenous adenosine. Importantly, when caffeine was administered at the supratherapeutic dose of 100 mg/kg, it no longer enhanced inflammation; it actually suppressed it. This anti-inflammatory effect is consistent with caffeine being a PDE inhibitor at high concentrations, because other PDE inhibitors have similar anti-inflammatory effects in general acute inflammation (Hasko et al. 1998; Nemeth et al. 1997).
8.2 Caffeine and Theophylline Reverse the Anti-inflammatory Effects of Methotrexate
Low-dose orally administered methotrexate is currently the gold standard therapy for the treatment of rheumatoid arthritis. Recent studies have demonstrated that most of the anti-inflammatory effects of methotrexate are mediated by enhanced adenosine release and activation of anti-inflammatory adenosine receptors (Cronstein 2005). Indeed, most of the genetic markers associated with response or lack of response to methotrexate are in enzymes inhibited by methotrexate polyglutamates that are involved in adenosine generation (Dervieux 2009; Dervieux et al. 2004, 2005, 2009; Weisman et al. 2006; Wessels et al. 2006a, b).
Because it is difficult to sample adenosine levels at inflamed sites in patients with rheumatoid arthritis and it is, therefore, difficult to validate the hypothesis that adenosine mediates the anti-inflammatory effects of methotrexate therapy, experiments were carried out with the adjuvant arthritis model of rheumatoid arthritis using adenosine receptor antagonists. In these studies, both theophylline and caffeine reversed the anti-inflammatory effects of methotrexate in rats with adjuvant arthritis (Montesinos et al. 2000) without affecting the course of the arthritis itself. This finding suggested that such commonly used adenosine receptor antagonists as caffeine might reverse the therapeutic effects of methotrexate therapy in patients as well. Indeed, a small prospective study by Nesher et al. (2003) demonstrated that patients started on methotrexate but told to abstain from caffeine responded significantly better than those who did not. Similar observations were made by Silke et al. (2001) of methotrexate in patients as well. In contrast, a larger retrospective study (Benito-Garcia et al. 2006) did not confirm the effect of caffeine consumption on the response to methotrexate; however, since all of the patients in this study had been taking methotrexate for longer than 2 years, it is likely that any patients who did not respond at all had already stopped methotrexate therapy by the time that the survey was done.
9 Conclusion
Both caffeine and theophylline play a variety of roles in regulating inflammatory responses. Although many of the effects of these commonly used methylxanthines are attributable to adenosine receptor blockade, these methylxanthines regulate inflammation by multiple mechanisms.
References
Baker AJ, Fuller RW (1992) Effect of cyclic adenosine monophosphate, 5′-(N-ethylcarboxyamido)-adenosine and methylxanthines on the release of thromboxane and lysosomal enzymes from human alveolar macrophages and peripheral blood monocytes in vitro. Eur J Pharmacol 211:157–161
Barnes PJ (2006) Theophylline for COPD. Thorax 61:742–744
Beavo JA, Rogers NL, Crofford OB, Baird CE, Hardman JG, Sutherland EW, Newman EV (1971) Effects of phosphodiesterase inhibitors on cyclic AMP levels and on lipolysis. Ann N Y Acad Sci 185:129–136
Benito-Garcia E, Heller JE, Chibnik LB, Maher NE, Matthews HM, Bilics JA, Weinblatt ME, Shadick NA (2006) Dietary caffeine intake does not affect methotrexate efficacy in patients with rheumatoid arthritis. J Rheumatol 33:1275–1281
Bruns RF, Lu GH, Pugsley TA (1986) Characterization of the A2 adenosine receptor labeled by [3H]NECA in rat striatal membranes. Mol Pharmacol 29:331–346
Chavez-Valdez R, Wills-Karp M, Ahlawat R, Cristofalo EA, Nathan A, Gauda EB (2009) Caffeine modulates TNF-alpha production by cord blood monocytes: the role of adenosine receptors. Pediatr Res 65:203–208
Che J, Chan ES, Cronstein BN (2007) Adenosine A2A receptor occupancy stimulates collagen expression by hepatic stellate cells via pathways involving protein kinase A, Src, and extracellular signal-regulated kinases 1/2 signaling cascade or p38 mitogen-activated protein kinase signaling pathway. Mol Pharmacol 72:1626–1636
Chen Y, Corriden R, Inoue Y, Yip L, Hashiguchi N, Zinkernagel A, Nizet V, Insel PA, Junger WG (2006) ATP release guides neutrophil chemotaxis via P2Y2 and A3 receptors. Science 314:1792–1795
Cosio BG, Tsaprouni L, Ito K, Jazrawi E, Adcock IM, Barnes PJ (2004) Theophylline restores histone deacetylase activity and steroid responses in COPD macrophages. J Exp Med 200:689–695
Cronstein BN (2005) Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis. Pharmacol Rev 57:163–172
Csoka B, Nemeth ZH, Virag L, Gergely P, Leibovich SJ, Pacher P, Sun CX, Blackburn MR, Vizi ES, Deitch EA, Hasko G (2007) A2A adenosine receptors and C/EBPbeta are crucially required for IL-10 production by macrophages exposed to Escherichia coli. Blood 110:2685–2695
Deaglio S, Dwyer KM, Gao W, Friedman D, Usheva A, Erat A, Chen JF, Enjyoji K, Linden J, Oukka M, Kuchroo VK, Strom TB, Robson SC (2007) Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med 204:1257–1265
Dervieux T (2009) Methotrexate pharmacogenomics in rheumatoid arthritis: introducing false-positive report probability. Rheumatology (Oxford) 48:597–598
Dervieux T, Furst D, Lein DO, Capps R, Smith K, Walsh M, Kremer J (2004) Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis. Arthritis Rheum 50:2766–2774
Dervieux T, Furst D, Lein DO, Capps R, Smith K, Caldwell J, Kremer J (2005) Pharmacogenetic and metabolite measurements are associated with clinical status in patients with rheumatoid arthritis treated with methotrexate: results of a multicentred cross sectional observational study. Ann Rheum Dis 64:1180–1185
Dervieux T, Wessels JA, van der Straaten T, Penrod N, Moore JH, Guchelaar HJ, Kremer JM (2009) Gene–gene interactions in folate and adenosine biosynthesis pathways affect methotrexate efficacy and tolerability in rheumatoid arthritis. Pharmacogenet Genomics
Eltzschig HK, Macmanus CF, Colgan SP (2008) Neutrophils as sources of extracellular nucleotides: functional consequences at the vascular interface. Trends Cardiovasc Med 18:103–107
Endres S, Fulle HJ, Sinha B, Stoll D, Dinarello CA, Gerzer R, Weber PC (1991) Cyclic nucleotides differentially regulate the synthesis of tumour necrosis factor-alpha and interleukin-1 beta by human mononuclear cells. Immunology 72:56–60
Erdmann AA, Gao ZG, Jung U, Foley J, Borenstein T, Jacobson KA, Fowler DH (2005) Activation of Th1 and Tc1 cell adenosine A2A receptors directly inhibits IL-2 secretion in vitro and IL-2-driven expansion in vivo. Blood 105:4707–4714
Feoktistov I, Biaggioni I (1995) Adenosine A2b receptors evoke interleukin-8 secretion in human mast cells. An enprofylline-sensitive mechanism with implications for asthma. J Clin Invest 96:1979–1986
Feoktistov I, Biaggioni I (1997) Adenosine A2B receptors. Pharmacol Rev 49:381–402
Fozard JR, Hannon JP (1999) Adenosine receptor ligands: potential as therapeutic agents in asthma and COPD. Pulm Pharmacol Ther 12:111–114
Fozard JR, Pfannkuche HJ, Schuurman HJ (1996) Mast cell degranulation following adenosine A3 receptor activation in rats. Eur J Pharmacol 298:293–297
Fredholm BB (2007) Adenosine, an endogenous distress signal, modulates tissue damage and repair. Cell Death Differ 14:1315–1323
Fredholm BB, Sandberg G (1983) Inhibition by xanthine derivatives of adenosine receptor-stimulated cyclic adenosine 3′,5′-monophosphate accumulation in rat and guinea-pig thymocytes. Br J Pharmacol 80:639–644
Fredholm BB, Zhang Y, van der Ploeg I (1996) Adenosine A2A receptors mediate the inhibitory effect of adenosine on formyl-Met-Leu-Phe-stimulated respiratory burst in neutrophil leucocytes. Naunyn Schmiedebergs Arch Pharmacol 354:262–267
Fredholm BB, Battig K, Holmen J, Nehlig A, Zvartau EE (1999) Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol Rev 51:83–133
Fredholm BB, Irenius E, Kull B, Schulte G (2001) Comparison of the potency of adenosine as an agonist at human adenosine receptors expressed in Chinese hamster ovary cells. Biochem Pharmacol 61:443–448
Fredholm BB, Chern Y, Franco R, Sitkovsky M (2007) Aspects of the general biology of adenosine A2A signaling. Prog Neurobiol 83:263–276
Gessi S, Merighi S, Varani K, Leung E, Mac Lennan S, Borea PA (2008) The A3 adenosine receptor: an enigmatic player in cell biology. Pharmacol Ther 117:123–140
Hasko G, Szabo C, Nemeth ZH, Salzman AL, Vizi ES (1998) Suppression of IL-12 production by phosphodiesterase inhibition in murine endotoxemia is IL-10 independent. Eur J Immunol 28:468–472
Hasko G, Pacher P, Deitch EA, Vizi ES (2007) Shaping of monocyte and macrophage function by adenosine receptors. Pharmacol Ther 113:264–275
Hasko G, Linden J, Cronstein B, Pacher P (2008) Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. Nat Rev Drug Discov 7:759–770
Hasko G, Csoka B, Nemeth ZH, Vizi ES, Pacher P (2009) A(2B) adenosine receptors in immunity and inflammation. Trends Immunol 30:263–270
Hichami A, Boichot E, Germain N, Legrand A, Moodley I, Lagente V (1995) Involvement of cyclic AMP in the effects of phosphodiesterase IV inhibitors on arachidonate release from mononuclear cells. Eur J Pharmacol 291:91–97
Holgate ST (2005) The Quintiles Prize Lecture 2004. The identification of the adenosine A2B receptor as a novel therapeutic target in asthma. Br J Pharmacol 145:1009–1015
Horrigan LA, Kelly JP, Connor TJ (2004) Caffeine suppresses TNF-alpha production via activation of the cyclic AMP/protein kinase A pathway. Int Immunopharmacol 4:1409–1417
Horrigan LA, Kelly JP, Connor TJ (2006) Immunomodulatory effects of caffeine: friend or foe? Pharmacol Ther 111:877–892
Inouye LK, Wharton W (1986) The relationship between intracellular cyclic AMP concentrations and the in vitro growth of macrophages. J Leukoc Biol 39:657–670
Ito K, Lim S, Caramori G, Cosio B, Chung KF, Adcock IM, Barnes PJ (2002) A molecular mechanism of action of theophylline: induction of histone deacetylase activity to decrease inflammatory gene expression. Proc Natl Acad Sci USA 99:8921–8926
Jin X, Shepherd RK, Duling BR, Linden J (1997) Inosine binds to A3 adenosine receptors and stimulates mast cell degranulation. J Clin Invest 100:2849–2857
Khoa ND, Montesinos MC, Reiss AB, Delano D, Awadallah N, Cronstein BN (2001) Inflammatory cytokines regulate function and expression of adenosine A(2A) receptors in human monocytic THP-1 cells. J Immunol 167:4026–4032
Meiners I, Hauschildt S, Nieber K, Munch G (2004) Pentoxyphylline and propentophylline are inhibitors of TNF-alpha release in monocytes activated by advanced glycation endproducts. J Neural Transm 111:441–447
Montesinos C, Yap JS, Desai A, Posadas I, McCrary CT, Cronstein BN (2000) Reversal of the antiinflammatory effects of methotrexate by the nonselective adenosine receptor antagonists theophylline and caffeine. Evidence that the antiinflammatory effects of methotrexate are mediated via multiple adenosine receptors in rat adjuvant arthritis. Arthritis Rheum 43:656–663
Mustafa SJ, Nadeem A, Fan M, Zhong H, Belardinelli L, Zeng D (2007) Effect of a specific and selective A(2B) adenosine receptor antagonist on adenosine agonist AMP and allergen-induced airway responsiveness and cellular influx in a mouse model of asthma. J Pharmacol Exp Ther 320:1246–1251
Nemeth ZH, Hasko G, Szabo C, Vizi ES (1997) Amrinone and theophylline differentially regulate cytokine and nitric oxide production in endotoxemic mice. Shock 7:371–375
Nemeth ZH, Leibovich SJ, Deitch EA, Sperlagh B, Virag L, Vizi ES, Szabo C, Hasko G (2003) Adenosine stimulates CREB activation in macrophages via a p38 MAPK-mediated mechanism. Biochem Biophys Res Commun 312:883–888
Nesher G, Mates M, Zevin S (2003) Effect of caffeine consumption on efficacy of methotrexate in rheumatoid arthritis. Arthritis Rheum 48:571–572
Ohta A, Sitkovsky M (2001) Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature 414:916–920
Ohta A, Lukashev D, Jackson EK, Fredholm BB, Sitkovsky M (2007) 1, 3, 7-trimethylxanthine (caffeine) may exacerbate acute inflammatory liver injury by weakening the physiological immunosuppressive mechanism. J Immunol 179:7431–7438
Polosa R, Holgate ST (2006) Adenosine receptors as promising therapeutic targets for drug development in chronic airway inflammation. Curr Drug Targets 7:699–706
Revan S, Montesinos MC, Naime D, Landau S, Cronstein BN (1996) Adenosine A2 receptor occupancy regulates stimulated neutrophil function via activation of a serine/threonine protein phosphatase. J Biol Chem 271:17114–17118
Ryzhov S, Goldstein AE, Biaggioni I, Feoktistov I (2006) Cross-talk between G(s)- and G(q)-coupled pathways in regulation of interleukin-4 by A(2B) adenosine receptors in human mast cells. Mol Pharmacol 70:727–735
Sawynok J, Yaksh TL (1993) Caffeine as an analgesic adjuvant: a review of pharmacology and mechanisms of action. Pharmacol Rev 45:43–85
Silke C, Murphy MS, Buckley T, Busteed S, Molloy MG, Phelan M (2001) The effects of caffeine ingestion on the efficacy of methotrexate. Rheumatology (Oxford) 40(Suppl 1):34
Sitkovsky MV (2009) T regulatory cells: hypoxia-adenosinergic suppression and re-direction of the immune response. Trends Immunol 30(3):102–108
Sullivan GW, Luong LS, Carper HT, Barnes RC, Mandell GL (1995) Methylxanthines with adenosine alter TNF alpha-primed PMN activation. Immunopharmacology 31:19–29
van Calker D, Muller M, Hamprecht B (1979) Adenosine regulates via two different types of receptors, the accumulation of cyclic AMP in cultured brain cells. J Neurochem 33:999–1005
Volonte C, D’Ambrosi N (2009) Membrane compartments and purinergic signalling: the purinome, a complex interplay among ligands, degrading enzymes, receptors and transporters. FEBS J 276:318–329
Walker BA, Rocchini C, Boone RH, Ip S, Jacobson MA (1997) Adenosine A2a receptor activation delays apoptosis in human neutrophils. J Immunol 158:2926–2931
Weisman MH, Furst DE, Park GS, Kremer JM, Smith KM, Wallace DJ, Caldwell JR, Dervieux T (2006) Risk genotypes in folate-dependent enzymes and their association with methotrexate-related side effects in rheumatoid arthritis. Arthritis Rheum 54:607–612
Wessels JA, de Vries-Bouwstra JK, Heijmans BT, Slagboom PE, Goekoop-Ruiterman YP, Allaart CF, Kerstens PJ, van Zeben D, Breedveld FC, Dijkmans BA, Huizinga TW, Guchelaar HJ (2006a) Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associated with single-nucleotide polymorphisms in genes coding for folate pathway enzymes. Arthritis Rheum 54:1087–1095
Wessels JA, Kooloos WM, Jonge RD, De Vries-Bouwstra JK, Allaart CF, Linssen A, Collee G, Sonnaville PD, Lindemans J, Huizinga TW, Guchelaar HJ (2006b) Relationship between genetic variants in the adenosine pathway and outcome of methotrexate treatment in patients with recent-onset rheumatoid arthritis. Arthritis Rheum 54:2830–2839
Yasui K, Hu B, Nakazawa T, Agematsu K, Komiyama A (1997) Theophylline accelerates human granulocyte apoptosis not via phosphodiesterase inhibition. J Clin Invest 100:1677–1684
Yasui K, Agematsu K, Shinozaki K, Hokibara S, Nagumo H, Nakazawa T, Komiyama A (2000a) Theophylline induces neutrophil apoptosis through adenosine A2A receptor antagonism. J Leukoc Biol 67:529–535
Yasui K, Agematsu K, Shinozaki K, Hokibara S, Nagumo H, Yamada S, Kobayashi N, Komiyama A (2000b) Effects of theophylline on human eosinophil functions: comparative study with neutrophil functions. J Leukoc Biol 68:194–200
Yegutkin GG (2008) Nucleotide- and nucleoside-converting ectoenzymes: important modulators of purinergic signalling cascade. Biochim Biophys Acta 1783(5):673–694
Zhong H, Shlykov SG, Molina JG, Sanborn BM, Jacobson MA, Tilley SL, Blackburn MR (2003) Activation of murine lung mast cells by the adenosine A3 receptor. J Immunol 171:338–345
Zhong H, Belardinelli L, Maa T, Feoktistov I, Biaggioni I, Zeng D (2004) A(2B) adenosine receptors increase cytokine release by bronchial smooth muscle cells. Am J Respir Cell Mol Biol 30:118–125
Zhong H, Belardinelli L, Maa T, Zeng D (2005) Synergy between A2B adenosine receptors and hypoxia in activating human lung fibroblasts. Am J Respir Cell Mol Biol 32:2–8
Zhong H, Wu Y, Belardinelli L, Zeng D (2006) A2B adenosine receptors induce IL-19 from bronchial epithelial cells, resulting in TNF-alpha increase. Am J Respir Cell Mol Biol 35:587–592
Zhou QY, Li C, Olah ME, Johnson RA, Stiles GL, Civelli O (1992) Molecular cloning and characterization of an adenosine receptor: the A3 adenosine receptor. Proc Natl Acad Sci USA 89:7432–7436
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer Berlin Heidelberg
About this chapter
Cite this chapter
Haskó, G., Cronstein, B. (2011). Methylxanthines and Inflammatory Cells. In: Methylxanthines. Handbook of Experimental Pharmacology, vol 200. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-13443-2_18
Download citation
DOI: https://doi.org/10.1007/978-3-642-13443-2_18
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-13442-5
Online ISBN: 978-3-642-13443-2
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)